Bulletin
Investor Alert

London Markets Open in:

BioNTech SE ADR

NAS: BNTX

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Dec 5, 2022, 7:56 p.m.

/zigman2/quotes/214419716/composite

$

166.00

Change

-0.71 -0.43%

Volume

Volume 10,332

Quotes are delayed by 20 min

/zigman2/quotes/214419716/composite

Previous close

$ 169.74

$ 166.71

Change

-3.03 -1.79%

Day low

Day high

$165.36

$171.36

Open

52 week low

52 week high

$117.08

$312.96

Open

Company Description

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem T...

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Valuation

P/E Current

3.62

P/E Ratio (with extraordinary items)

3.83

P/E Ratio (without extraordinary items)

5.17

Price to Sales Ratio

2.98

Price to Book Ratio

4.62

Price to Cash Flow Ratio

63.67

Enterprise Value to EBITDA

1.89

Enterprise Value to Sales

1.95

Efficiency

Total Asset Turnover

2.15

Liquidity

Current Ratio

4.32

Quick Ratio

4.17

Cash Ratio

0.49

Profitability

Gross Margin

99.49

Operating Margin

92.93

Pretax Margin

79.29

Net Margin

54.24

Return on Assets

116.75

Return on Equity

160.03

Return on Total Capital

263.18

Capital Structure

Total Debt to Total Assets

1.90

Officers and Executives

Name Age Officer Since Title
Mr. Helmut Jeggle 51 2008 Chairman-Supervisory Board
Dr. Ugur Sahin 56 2008 Chief Executive Officer
Dr. Sierk Pötting 48 2014 Chief Operating & Financial Officer
Mr. Jens Holstein 56 2021 Chief Financial Officer
Dr. Özlem Türeci 54 2008 Chief Medical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
/news/latest/company/us/bntx

MarketWatch News on BNTX

  1. China begins to loosen COVID rules

    11:31 a.m. Dec. 5, 2022

    - Jaimy Lee

  2. Pfizer and BioNTech say bivalent booster increased neutralizing antibodies vs. new omicron variants by 4.8 to 11.1-fold

    6:48 a.m. Nov. 18, 2022

    - Ciara Linnane

  3. Pfizer and BioNTech report bivalent booster increased neutralizing antibodies 3.2 to 4.8-fold vs. original COVID vaccines

    6:47 a.m. Nov. 18, 2022

    - Ciara Linnane

  4. Pfizer, BioNTech booster of bivalent COVID vaccine recommended for use in EU for 5-11 year olds

    9:48 a.m. Nov. 10, 2022

    - Tomi Kilgore

  5. Loading more headlines...
/news/nonmarketwatch/company/us/bntx

Other News on BNTX

  1. BioNTech (BNTX) Inks Research Deal With Ryvu Therapeutics

    10:07 a.m. Dec. 1, 2022

    - Zacks.com

  2. Novavax (NVAX) COVID Jab Gets Expanded Label in WHO's EUL

    10:20 a.m. Nov. 30, 2022

    - Zacks.com

  3. Chinese Protests Put Xi Jinping in a Bind

    4:56 p.m. Nov. 28, 2022

    - Lingling Wei

  4. Novavax (NVAX) Stock Nosedives 88% This Year: Here's Why

    12:30 p.m. Nov. 28, 2022

    - Zacks.com

  5. Novavax (NVAX) Cancels COVID Jab Supply Deal With GAVI

    12:35 p.m. Nov. 23, 2022

    - Zacks.com

  6. New Covid-19 Booster Shots For This Fall: What to Know

    2:01 p.m. Nov. 22, 2022

    - Peter Loftus

  7. IDNA: Healthcare Dashboard For November

    12:26 p.m. Nov. 16, 2022

    - Seeking Alpha

  8. MARK ASSET MANAGEMENT LP Buys 2, Sells 3 in 3rd Quarter

    4:00 p.m. Nov. 15, 2022

    - GuruFocus.com

  9. Gates Foundation added LumiraDX, pared Atreca stake in Q3

    6:17 p.m. Nov. 14, 2022

    - Seeking Alpha

  10. Loading more headlines...

At a Glance

BioNTech SE

An der Goldgrube 12

Mainz, Rheinland-Pfalz 55131

Phone

49 613190840

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

$22.43B

Net Income

$12.17B

Employees

3,082

/news/pressrelease/company/us/bntx

Press Releases on BNTX

  1. Biontech Se BNTX Pivots Trading Plans and Risk Controls

    4:45 a.m. Nov. 30, 2022

    - Stock Traders Daily

  2. Biontech Se BNTX Trading Advice

    2:00 p.m. Nov. 20, 2022

    - Stock Traders Daily

  3. Learn to Evaluate Biontech Se (BNTX) using the Charts

    9:36 p.m. Nov. 10, 2022

    - Stock Traders Daily

  4. Busy Earnings Season Churns On

    2:57 p.m. Nov. 4, 2022

    - Baystreet.ca

  5. Loading more headlines...
Link to MarketWatch's Slice.